Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
66%
Asthma
56%
Health Care Cost
34%
Cost-Effectiveness Analysis
33%
Global Disease Burden
30%
Medication Compliance
26%
Drug Therapy
25%
Disease
23%
Prevalence
21%
Primary Health Care
19%
Patient with Asthma
17%
Randomized Controlled Trial
14%
Systematic Review
13%
Disability Adjusted Life Years
11%
Health Care
9%
Patient with Type 2 Diabetes
8%
Low and Middle Income Countries
8%
Injury
8%
COVID-19
7%
Maturity Onset Diabetes of the Young
7%
Diabetes
6%
Chronic Respiratory Tract Disease
6%
Dry Powder Inhaler
6%
Mortality Rate
5%
Antihypertensive Agent
5%
Health Status
5%
Symptom
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Asthma
92%
Prevalence
28%
Disease
27%
Global Disease Burden
20%
Non Insulin Dependent Diabetes Mellitus
17%
Randomized Controlled Trial
17%
Cohort Study
13%
Therapeutic Drug Monitoring
13%
Community Pharmacy
10%
Dry Powder Inhaler
10%
Pharmacotherapy
9%
Comorbidity
8%
Pharmaceutical Care
8%
Cross-Sectional Study
8%
Metered-Dose Inhaler
7%
Respiratory Tract Disease
7%
Antihypertensive Agent
7%
Symptom
7%
Adverse Drug Reaction
7%
Injury
6%
Fluticasone
6%
Biological Product
6%
Chronic Respiratory Tract Disease
6%
Allergic Rhinitis
5%
Community Acquired Pneumonia
5%
Budesonide Plus Formoterol
5%
HIV
5%
Infection
5%
Varenicline
5%
Adverse Event
5%
Keyphrases
Medication Adherence
31%
Chronic Obstructive Pulmonary Disease
27%
Asthma
26%
Cost-effectiveness
17%
Type 2 Diabetic Patients
11%
Non-adherence
10%
Cost-effectiveness Analysis
10%
Pharmacist Intervention
7%
Pharmacologic
7%
Chronic Obstructive Pulmonary Disease Patient
7%
Diabetes
6%
Primary Care
6%
Netherlands
6%
Comorbidity
6%
COPD Patients
6%
Pharmacist
6%
Dutch
6%
Community Pharmacy
6%
Economic Impact
6%
Medication Use
6%
Healthcare Professionals
5%
Non-adherent
5%
Antihypertensive Drugs
5%
Maintenance Treatment
5%
Test of Adherence to Inhalers
5%
Kyrgyzstan
5%
